RAC1, Rac family small GTPase 1, 5879

N. diseases: 415; N. variants: 20
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010606
Disease: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
0.010 Biomarker disease BEFREE This study aimed to explore whether RhoG/Rac1 was involved in migration and invasion of salivary adenoid cystic carcinoma. 31793126 2020
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.010 AlteredExpression phenotype BEFREE Placental mTORC2 inhibition in human IUGR may contribute to decreased placental amino acid transfer and reduced fetal growth mediated by down-regulation of Cdc42 and Rac1. 31825077 2020
CHROMOSOME 8p11 MYELOPROLIFERATIVE SYNDROME
0.010 Biomarker disease BEFREE RAC1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome. 31221776 2020
CUI: C3828416
Disease: Radiation Damage
Radiation Damage
0.010 Biomarker disease BEFREE Intestinal epithelial and tumor cell lines, namely MODE-k and CT-26, were used to further study the role of Rac1 inhibition on radiation damage. 31786196 2020
CUI: C0001956
Disease: Alcohol Use Disorder
Alcohol Use Disorder
0.010 Biomarker disease BEFREE Our data show that Rac1 and cofilin activity are key to determining the rate of acquisition of alcohol preference, revealing a critical role of actin dynamics regulation in the development of voluntary self-administration in <i>Drosophila</i><b>SIGNIFICANCE STATEMENT</b> The risks for developing an alcohol use disorder (AUD) are strongly determined by genetic factors. 31558618 2019
CUI: C0002622
Disease: Amnesia
Amnesia
0.010 AlteredExpression disease BEFREE Thus, multiple lines of evidence corroborate in supporting the idea that inhibition of Rac1 activity is effective for treating AD-related memory loss. 31321704 2019
CUI: C0003467
Disease: Anxiety
Anxiety
0.010 GeneticVariation disease BEFREE In addition, NAc D<sub>1</sub>R deletion aggravated METH withdrawal-induced spatial learning and memory impairment by suppressing Rac1 signaling but not Cdc42 signaling, while NAc D<sub>2</sub>R deletion aggravated METH withdrawal-induced anxiety without affecting Rac1 or Cdc42 signaling. 31060803 2019
CUI: C0003469
Disease: Anxiety Disorders
Anxiety Disorders
0.010 GeneticVariation group BEFREE In addition, NAc D<sub>1</sub>R deletion aggravated METH withdrawal-induced spatial learning and memory impairment by suppressing Rac1 signaling but not Cdc42 signaling, while NAc D<sub>2</sub>R deletion aggravated METH withdrawal-induced anxiety without affecting Rac1 or Cdc42 signaling. 31060803 2019
CUI: C0009241
Disease: Cognition Disorders
Cognition Disorders
0.010 Biomarker group BEFREE Together, our results implicate Rac1 hyperactivity in synaptic plasticity and cognitive deficits observed in <i>Cc2d1a</i> cKO mice and reveal a novel role for CC2D1A in regulating hippocampal synaptic function.<b>SIGNIFICANCE STATEMENT</b> CC2D1A is abundantly expressed in the brain, but there is little known about its physiological function. 30992372 2019
CUI: C0015967
Disease: Fever
Fever
0.010 Biomarker phenotype BEFREE Our investigation confirmed the validity of our current strategy for deep hyperthermia in the head & neck based on a combination of THQ and TC25. 30973030 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.010 Biomarker phenotype BEFREE In the present study, we evaluated RAc1 nano particle effects on hyperalgesia and liver hepcidin and serum IL-1β and TNF-α expression levels during acute and chronic phases of adjuvant-induced inflammation in male rats and compared its effects with Deferoxamine. 30776642 2019
CUI: C0030805
Disease: Bullous pemphigoid
Bullous pemphigoid
0.010 Biomarker disease BEFREE These cellular alterations are reversed by pharmacological inhibitors of Rac1 or the proteasome pathway, suggesting that Rac1 and proteasome activation are involved in the effects of BP IgG on cultured keratinocytes. 30809225 2019
CUI: C0035334
Disease: Retinitis Pigmentosa
Retinitis Pigmentosa
0.010 Biomarker disease BEFREE Ameliorative effects of UPARANT were likely to occur through an inhibitory action on up-regulated activity of the αvβ3 integrin/Rac1 pathway that was suggested as a novel target for the development of therapeutic approaches against RP. 31251468 2019
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma
0.010 AlteredExpression disease BEFREE A total of 26 of these miRNAs targeted genes involved in pathways connected to the three main features of SSc and to cancer development including Epidermal growth factor (EGF) receptor, ErbB1 downstream, Sphingosine 1 phosphate receptor 1 (S1P1), Activin receptor-like kinase 1 (ALK1), Endothelins, Ras homolog family member A (RhoA), Class I Phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), p38 mitogen-activated protein kinase (MAPK), Ras-related C3 botulinum toxin substrate 1 (RAC1), Transforming growth factor (TGF)-beta receptor, Myeloid differentiation primary response 88 (MyD88) and Toll-like receptors (TLRs) pathways. 30866419 2019
CUI: C0043119
Disease: Werner Syndrome
Werner Syndrome
0.010 Biomarker disease BEFREE Regarding motility, we propose that WRN affects Rac1/FAK/ß1-integrin-related mechanisms regulating cell polarity and directed motility. 30413344 2019
CUI: C0152132
Disease: Hypertensive Retinopathy
Hypertensive Retinopathy
0.010 GeneticVariation disease BEFREE Eye Drop Instillation of the Rac1 Modulator CNF1 Attenuates Retinal Gliosis and Ameliorates Visual Performance in a Rat Model of Hypertensive Retinopathy. 31128161 2019
Inflammatory disease of the central nervous system
0.010 AlteredExpression group BEFREE Proteins belonging to the Rho GTPase family, particularly Rac1, are involved in the activation of Müller glia and in the progression of photoreceptor degeneration, and may thus represent a novel candidate for therapeutic intervention following central nervous system inflammation. 31128161 2019
Congenital contractural arachnodactyly
0.010 AlteredExpression disease BEFREE Pami significantly decreased the protein expression levels of Rac1 in the MVA signaling pathway and may therefore be beneficial for developing a novel chemotherapeutic method for CCA. 31611937 2019
CUI: C0279613
Disease: Childhood Alveolar Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
0.010 Biomarker disease BEFREE Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma. 30833420 2019
CUI: C0344720
Disease: Left atrial dilatation
Left atrial dilatation
0.010 Biomarker disease BEFREE Finerenone prevented left atrial dilatation (6.4 ± 1.5 vs. 4.7 ± 1.4 mg, p = 0.004) and left atrial fibrosis (17.8 ± 3.1 vs. 12.8 ± 3.1%, p = 0.046) compared to vehicle-treated RacET mice. 31283930 2019
CUI: C0346429
Disease: Multiple malignancy
Multiple malignancy
0.010 Biomarker phenotype BEFREE We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. 31350524 2019
CUI: C0393642
Disease: Sepsis-Associated Encephalopathy
Sepsis-Associated Encephalopathy
0.010 Biomarker disease BEFREE In conclusion, β-elemene effectively alleviated SAE in mice and inhibited the RAC1/MLK3/p38 signaling pathway in microglia, and might be an eligible potential candidate for SAE treatment. 31068775 2019
CUI: C0598608
Disease: Hyperhomocysteinemia
Hyperhomocysteinemia
0.010 Biomarker disease BEFREE Rac1 GTPase Inhibition Blocked Podocyte Injury and Glomerular Sclerosis during Hyperhomocysteinemia via Suppression of Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation. 31266025 2019
CUI: C0751295
Disease: Memory Loss
Memory Loss
0.010 AlteredExpression phenotype BEFREE Thus, multiple lines of evidence corroborate in supporting the idea that inhibition of Rac1 activity is effective for treating AD-related memory loss. 31321704 2019
CUI: C0878544
Disease: Cardiomyopathies
Cardiomyopathies
0.010 AlteredExpression group BEFREE Cardiac Rac1 activity was positively correlated with the ELMO1 levels, and oral administration of a pan-Rac inhibitor, EHT1864, partially mitigated cardiomyopathy of the ELMO1 hypermorphs. 31217360 2019